Jeffery Errington
Oprichter bij Demuris Ltd.
Actieve functies van Jeffery Errington
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Demuris Ltd.
Demuris Ltd. Medical DistributorsDistribution Services Demuris Ltd. develops portfolio of novel antibiotics. The firm is an antibiotic discovery company, which provides technologies of genome engineering, natural product sourcing, and target-based screening. It's products include broad spectrum, gram positive, tuberculosis, anti-fungal, and anti-cancer programs. The company was founded by Jeffery Errington on May 22, 2007 and is headquartered in Newcastle-upon-Tyne, the United Kingdom. | Directeur/Bestuurslid | 03-09-2007 | - |
Algemeen Directeur | 22-05-2007 | - | |
Oprichter | 22-05-2007 | - |
Loopbaan van Jeffery Errington
Eerdere bekende functies van Jeffery Errington
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
BIOTA HOLDINGS LTD. | Directeur/Bestuurslid | 02-02-2010 | 12-08-2013 |
Independent Dir/Board Member | 01-02-2010 | 12-08-2013 | |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Directeur/Bestuurslid | 09-11-2012 | 12-08-2013 |
The University of Newcastle | Corporate Officer/Principal | 28-01-2011 | - |
University of Oxford | Corporate Officer/Principal | - | - |
Prolysis Ltd.
Prolysis Ltd. Pharmaceuticals: MajorHealth Technology Prolysis Ltd. develops and manufactures pharmaceutical products. It develops antibacterial therapy to treat drug resistant infections. The company was founded in 1998 and is headquartered in Kidlington, UK. | Directeur/Bestuurslid | - | - |
Hoofd Techniek/Wetenschap/O&O | - | - | |
Oprichter | - | - |
Opleiding van Jeffery Errington
University of Oxford | Graduate Degree |
The University of Newcastle | Undergraduate Degree |
Statistieken
Internationaal
Verenigd Koninkrijk | 4 |
Australië | 3 |
Verenigde Staten | 2 |
Operationeel
Director/Board Member | 4 |
Founder | 2 |
Corporate Officer/Principal | 2 |
Sectoraal
Health Technology | 4 |
Consumer Services | 3 |
Distribution Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 4 |
---|---|
Prolysis Ltd.
Prolysis Ltd. Pharmaceuticals: MajorHealth Technology Prolysis Ltd. develops and manufactures pharmaceutical products. It develops antibacterial therapy to treat drug resistant infections. The company was founded in 1998 and is headquartered in Kidlington, UK. | Health Technology |
Biota Holdings Pty Ltd.
Biota Holdings Pty Ltd. Pharmaceuticals: MajorHealth Technology Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia. | Health Technology |
Demuris Ltd.
Demuris Ltd. Medical DistributorsDistribution Services Demuris Ltd. develops portfolio of novel antibiotics. The firm is an antibiotic discovery company, which provides technologies of genome engineering, natural product sourcing, and target-based screening. It's products include broad spectrum, gram positive, tuberculosis, anti-fungal, and anti-cancer programs. The company was founded by Jeffery Errington on May 22, 2007 and is headquartered in Newcastle-upon-Tyne, the United Kingdom. | Distribution Services |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
- Beurs
- Insiders
- Jeffery Errington
- Ervaring